SEC Form 4 · accession 0000886163-19-000004
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Higgins
Officer — Chief Executive Officer · Director
Period of report
Jan 10, 2019
Accepted (ET)
Jan 14, 2019 · 9:16 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 10, 2019 | M | 4,000 | $16.14 | A | 89,419 | D | |
| Common Stock | Jan 10, 2019 | M | 29,790 | $16.14 | A | 119,209 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F1 | $16.14 | Jan 10, 2019 | M | 29,790 | D | — | Feb 15, 2019 | Common Stock | 29,790 | 0 | D |
| Non-Qualified Stock Option (right to buy)F1 | $16.14 | Jan 10, 2019 | M | 4,000 | D | — | Feb 15, 2019 | Common Stock | 4,000 | 0 | D |
Explanation of responses
- F1Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 2/15/09.